Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825983 | 0.93 | MAPK8 (0.53) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4822049 | 0.90 | MAPK8 (0.50) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL5359759 | 0.90 | MAPK8 (0.54) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4822018 | 0.88 | MAPK8 (0.50) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4830161 | 0.88 | MAPK8 (0.52) | MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL5405985 | 0.86 | MAPK8 (0.54) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4825735 | 0.85 | MAPK8 (0.55) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4830196 | 0.85 | MAPK8 (0.48) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4826009 | 0.84 | MAPK8 (0.53) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4830159 | 0.83 | MAPK8 (0.44) | MAPK8HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | claimed |
| EP-1252158-B1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-04-20 | — | — | EP | claimed |
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1252158-B1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| EP-1252158-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PDE4B, PDE4A, NOX4 | MAPK8 1820/4885HPGD 22/4885LMNA 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.